![Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record](https://www.enr.com/ext/resources/Issues/MidAtlantic_Issues/2018/10-October/22-Oct/teva-pilot-plant01.jpg)
Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record
![Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210831005934/en/902034/23/MedinCell_LOGO.jpg)
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
![Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study | Molecular Psychiatry Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study | Molecular Psychiatry](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41380-022-01803-4/MediaObjects/41380_2022_1803_Fig1_HTML.png)
Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study | Molecular Psychiatry
![Teva abandons Ajovy's cluster headache ambitions, clearing a path for Lilly to forge a new market | Fierce Pharma Teva abandons Ajovy's cluster headache ambitions, clearing a path for Lilly to forge a new market | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1556112787/ajovy.jpg/ajovy.jpg?VersionId=4xAKjxsKE0QhqsTM9u9hdpb_E_PE_A2a)
Teva abandons Ajovy's cluster headache ambitions, clearing a path for Lilly to forge a new market | Fierce Pharma
![The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet](https://www.thelancet.com/cms/asset/c652217f-870a-4a98-976d-c433af9ee115/gr1.jpg)
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet
![Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com](https://images.law.com/contrib/content/uploads/sites/292/2022/11/Teva-767x633.jpg)
Boston Jury Awards Teva Pharmaceuticals $176.5M for Eli Lilly's Migraine Medication Patent Infringement | Law.com
![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210408005437/en/868792/5/Teva_Canada_-_AJOVY_Autoinjector.jpg)